Immunotherapy of multiple myeloma: the start of a long and tortuous journey

References

• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121(5), 749–757 (2003).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract. Res. Clin. Haematol..12(1–2), 171–191 (1999).
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Eng. J. Med.348(19), 1875–1883 (2003).
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J. Clin. Oncol.23(15), 3412–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet367(9513), 825–831 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Musto P et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer104(7), 1428–1433 (2005).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau JL et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J. Clin. Oncol.24(S18) (2006) (Abstract 1).
   Google Scholar
• Dingli D, Rajkumar SV, Nowakowski GS et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a Phase II trial. Haematologica90(12), 1650–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood106(1), 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Sidra G, Williams CD, Russell NH et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica91(6), 862–863 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106(11), (2005) (Abstract 781).
   Google Scholar
• Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood89(3), 789–793 (1997).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J-L, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med.349(26), 2495–2502 (2003).
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr. Opin. Oncol.17(2), 93–98 (2005).
   PubMed Web of Science ®Google Scholar
• Brinker BT, Waller EK, Leong T et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer106(10), 2171–2180 (2006).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood108(10), 3289–3294 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer106(6), 1316–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.352(24), 2487–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Wang M, Knight R, Dimopoulos M et al. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma. Presented at: ASCO Annual Meeting Atlanta, GA, USA, June 2–6 (2006).
   Google Scholar
• Gale RP, Horowitz MM, Bortin MM. IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplant.4(Suppl. 3), 83–84 (1989).
   Google Scholar
• Hughes TP, Economou K, Mackinnon S et al. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br. J. Haematol.73(4), 462–467 (1989).
   PubMed Web of Science ®Google Scholar
• Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for the treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Bensinger W, Buckner C, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood88(7), 2787–2793 (1996).
   PubMed Web of Science ®Google Scholar
• Corradini P, Voena C, Tarella C et al. Molecular and clinical remission in multiple myeloma: role of autologous and allogeneic transplantation of haematopoietic cells. J. Clin. Oncol.17, 208–215 (1999).
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Martino R, Alegre A et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br. J. Haematol.121(1), 104–108 (2003).
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole D, Jaganath S et al. Graft-versus-myeloma effect: proof of principle. Blood87, 1196–1199 (1996).
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Petersen EJ, Lokhorst HM et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant.22(11), 1057–1063 (1998).
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood105(11), 4532–4539 (2005).
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood90(10), 4206–4211 (1997).
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol.18(16), 3031–3037 (2000).
   PubMed Web of Science ®Google Scholar
• Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant.26(11), 1179–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Huff CA, Jones RJ. Bone marrow transplantation for multiple myeloma: where we are today. Curr. Opin. Oncol.14(2), 147–151 (2002).
   Google Scholar
• Cook G, Campbell JD. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev.13(3), 151–162 (1999).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet345(8956), 1016–1020 (1995).
   PubMed Web of Science ®Google Scholar
• Yiwen L, Bendandi M, Deng Y et al. Tumour-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood96, 2828–2833 (2000).
   Google Scholar
• Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell106(3), 255–258 (2001).
   PubMed Web of Science ®Google Scholar
• Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev.199, 9–26 (2004).
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Iwagaki H, Mizuno S, Akashi K. The majority of plasmacytoid dendritic cells originate from myeloid progenitors in murine hematopoiesis. Exp. Hematology31(7 Suppl. 1), S195 (2003).
   Google Scholar
• Matzinger P. An innate sense of danger. Semin. Immunol.10(5), 399–415 (1998).
   PubMed Web of Science ®Google Scholar
• Ohl L, Mohaupt M, Czeloth N et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity21(2), 279–188 (2004).
   PubMed Web of Science ®Google Scholar
• Beckmann JH, Yan S, Luhrs H et al. Prolongation of allograft survival in ccr7-deficient mice. Transplantation77(12), 1809–1814 (2004).
   PubMed Web of Science ®Google Scholar
• Qu C, Edwards EW, Tacke F et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J. Exp. Med.200(10), 1231–1241 (2004).
   PubMed Web of Science ®Google Scholar
• Sebastiani S, Albanesi C, De PO et al. The role of chemokines in allergic contact dermatitis. Arch. Dermatol. Res.293(11), 552–559 (2002).
   PubMed Web of Science ®Google Scholar
• Marsland BJ, Battig P, Bauer M et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity22(4), 493–505 (2005).
   PubMed Web of Science ®Google Scholar
• Granucci F, Vizzardelli C, Pavelka N et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol.2(9), 882–888 (2001).
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill D, Bhardwaj N. Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J. Clin. Oncol.22(18), 3834–3835 (2004).
   Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med.193(2), 233–238 (2001).
   PubMed Web of Science ®Google Scholar
• Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol.2(7), 585–589 (2001).
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol.22(7), 394–400 (2001).
   PubMed Web of Science ®Google Scholar
• Fearnley DB, McLellan AD, Mannering SI, Hock BD, Hart DN. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood89(10), 3708–3716 (1997).
   PubMed Web of Science ®Google Scholar
• Lopez JA, Bioley G, Turtle CJ et al. Single step enrichment of blood dendritic cells by positive immunoselection. J. Immunol. Methods274(1–2), 47–61 (2003).
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Munster DJ, Clark GJ et al. Characterization of human blood dendritic cell subsets. Blood100(13), 4512–4520 (2002).
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol.165(11), 6037–6046 (2000).
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair S, Fernandez-Casal M et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol.18(23), 3883–3893 (2000).
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med.184(5), 1953–1962 (1996).
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β and interleukin-10. Blood98(10), 2992–2998 (2001).
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100(1), 230–237 (2002).
   PubMed Web of Science ®Google Scholar
• Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature360(6401), 258–261 (1992).
   PubMed Web of Science ®Google Scholar
• Zhu K, Shen Q, Ulrich M, Zheng M. Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Chinese Med. J.113(12), 1124–1128 (2000).
   Google Scholar
• Ferlazzo G, Klein J, Paliard X, Wei WZ, Galy A. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J. Immunother.23(1), 48–58 (2000).
   PubMed Web of Science ®Google Scholar
• Caux C, Massacrier C, Dezutter-Dambuyant C et al. Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. J. Immunol.155(11), 5427–5435 (1995).
   PubMed Web of Science ®Google Scholar
• Dong R, Cwynarski K, Entwistle A et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood101(9), 3560–3567 (2003).
   PubMedGoogle Scholar
• Thurnher M, Papesh C, Ramoner R et al.In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp. Hematol.25(3), 232–237 (1997).
   Google Scholar
• Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods196(2), 137–151 (1996).
   PubMed Web of Science ®Google Scholar
• Tarte K, Fiol G, Rossi JF, Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia14(12), 2182–2192 (2000).
   PubMed Web of Science ®Google Scholar
• De Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res.9(14), 5091–5100 (2003).
   Google Scholar
• De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res.63(1), 12–17 (2003).
   PubMed Web of Science ®Google Scholar
• Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J. Leukocyte Biol.66(6), 981–988 (1999).
   PubMed Web of Science ®Google Scholar
• Brown R, Murray A, Pope B et al. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β in patients with myeloma. Br. J. Haematol.125(6), 743–748 (2004).
   PubMed Web of Science ®Google Scholar
• Villunger A, Egle A, Marschitz I et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood90(1), 12–20 (1997).
   PubMed Web of Science ®Google Scholar
• Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κ B activation in hemopoietic progenitor cells. J. Immunol.160(3), 1224–1232 (1998).
   PubMed Web of Science ®Google Scholar
• Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat. Med.2(12), 1367–1370 (1996).
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med.4(1), 43–49 (1998).
   PubMed Web of Science ®Google Scholar
• Treon SP, Maimonis P, Chauhan D, Anderson KC. Soluble Muc-1 is elevated in multiple myeloma (MM) bone marrow (BM) plasma and inhibits T cell proliferation. Blood92(10 Suppl. 1), A411 (1998).
   Google Scholar
• Sauter B, Albert ML, Francisco L et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med.191(3), 423–434 (2000).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood100(6), 2195–2202 (2002).
   PubMed Web of Science ®Google Scholar
• Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood96(2), 671–675 (2000).
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Abe M, Oshima T et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br. J. Haematol.125(1), 38–41 (2004).
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Nasser V, Avet-Loiseau H et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood101(12), 4998–5006 (2003).
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Szydlo R et al. Serum levels of macrophage inflammatory protein-1 α (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br. J. Haematol.123(1), 106–109 (2003).
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Franchin G, Williams PJ et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood102(1), 311–319 (2003).
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Gries M, Janz M et al. Macrophage inflammatory protein 1-α (MIP-1 α ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood101(9), 3568–3573 (2003).
   PubMed Web of Science ®Google Scholar
• Michigami T, Shimizu N, Williams PJ et al. Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α 4β 1-integrin enhances production of osteoclast-stimulating activity. Blood96(5), 1953–1960 (2000).
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Khurram R, Aldrich WA et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer89(12), 2646–2654 (2000).
   PubMed Web of Science ®Google Scholar
• Blocklet D, Toungouz M, Kiss R et al.111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur. J. Nucl. Med. Mol. Imag.30(3), 440–447 (2003).
   PubMed Web of Science ®Google Scholar
• Yi Q, Freeman ME, Szmania S et al. Intranodal vaccination with idiotype-pulsed dendritic cells induces potent and long-lasting cellular and humoral immune responses in myeloma patients. Blood102 (2003) (Abstract 5277).
   Google Scholar
• Beckhove P, Witzens M, Choi C et al. MUC1-reactive cytotoxic memory T cells in bone marrow of multiple myeloma patients. Blood102 (2003) (Abstract 5227).
   Google Scholar
• Yi Q, Osterborg A, Bergenbrant S et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood86(8), 3043–3049 (1995).
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Zhan F et al. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood105(10), 3939–3944 (2005).
   Google Scholar
• Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia11(8), 1312–1317 (1997).
   PubMed Web of Science ®Google Scholar
• Raitakari M, Brown RD, Gibson J, Joshua DE. T cells in myeloma. Hematol. Oncol.21(1), 33–42 (2003).
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Gambell P, Ritchie D et al. The prognostic effect of CD57+ cytotoxic T cells in patients with multiple myeloma treated with thalidomide. Clin. Cancer Res. (2006) (In Press).
   Google Scholar
• Noonan K, Matsui W, Serafini P et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res.65(5), 2026–2034 (2005).
   PubMed Web of Science ®Google Scholar
• Teague RM, Sather BD, Sacks JA et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med.12(3), 335–341 (2006).
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood96(8), 2828–2833 (2000).
   PubMed Web of Science ®Google Scholar
• Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood97(6), 1750–1755 (2001).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood91(7), 2459–2466 (1998).
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood101(11), 4607–4610 (2003).
   PubMed Web of Science ®Google Scholar
• Stritzke J, Zunkel T, Steinmann J et al. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br. J. Haematol.120(1), 27–35 (2003).
   PubMed Web of Science ®Google Scholar
• King CA, Spellerberg MB, Zhu D et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med.4(11), 1281–1286 (1998).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A toll-like receptor recognizes bacterial DNA. Nature408(6813), 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Coscia M, Mariani S, Battaglio S et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia18(1), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Redfern CH, Guthrie TH, Bessudo A et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol.24(19), 3107–3112 (2006).
   PubMed Web of Science ®Google Scholar
• Borrello I, Biedrzycki B, Sheets N et al. Autologous tumor combined with a GM–CSF-secreting cell line vaccine (GVAX®) following autologous stem cell transplant (ASCT) in multiple myeloma. Blood104(11) (2004) (Abstract 440).
   Google Scholar
• Reichardt V, Okada C, Liso A et al. Idiotype vaccination using dendritic cells afterautologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood93, 2411–2419 (1999).
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant.6(6), 621–627 (2000).
   PubMed Web of Science ®Google Scholar
• Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer83(2), 215–222 (1999).
   PubMed Web of Science ®Google Scholar
• Reichardt VL, Milazzo C, Brugger W et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica88(10), 1139–1149 (2003).
   PubMed Web of Science ®Google Scholar
• Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood99(9), 3280–3285 (2002).
   PubMed Web of Science ®Google Scholar
• Szmania SM, Rosen NA, Freeman J et al. Cryopreserved tumor protein loaded dendritic cell vaccines induce potent immune responses in patients with poor prognosis multiple myeloma. Blood102, (2003) (Abstract 1652).
   Google Scholar
• Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J. Transl. Med.2(1), 27 (2004).
   PubMedGoogle Scholar
• Feijoo E, Alfaro C, Mazzolini G et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int. J. Cancer116(2), 275–281 (2005).
   PubMed Web of Science ®Google Scholar
• Rice A, Hart D. Technology evaluation: APC-80200, Dendreon. Curr. Opin. Mol. Ther.4(5), 523–527 (2002).
   PubMedGoogle Scholar
• Rew SB, Peggs K, Sanjuan I et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin. Cancer Res.11(9), 3377–3384 (2005).
   PubMed Web of Science ®Google Scholar
• Jalili A, Ozaki S, Hara T et al. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood106(10), 3538–3545 (2005).
   PubMed Web of Science ®Google Scholar
• Azuma T, Otsuki T, Kuzushima K et al. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin. Cancer Res.10(21), 7402–7412 (2004).
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med.195(1), 125–133 (2002).
   PubMed Web of Science ®Google Scholar
• Batchu RB, Moreno AM, Szmania SM et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res.65(21), 10041–10049 (2005).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α−chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol.155(3), 1151–1164 (1995).
   PubMed Web of Science ®Google Scholar
• Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med.184(2), 387–396 (1996).
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer93(2), 243–251 (2001).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev.182, 18–32 (2001).
   PubMed Web of Science ®Google Scholar
• Prabhala R, Neri P, Tassone P et al. Dysregulated CD4+CD25+ T-regulatory cells and TLRs in myeloma. Blood104(11) (2004) (Abstract 2466).
   Google Scholar
• Banerjee D, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine matured DCs in myeloma patients. Blood108(8), 2655–2661 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. Il-2 administration increases CD4+ CD25hi FoxP3+ regulatory T cells in cancer patients. Blood107(6), 2409–2414 (2006).
   PubMed Web of Science ®Google Scholar
• Mesel-lemoine M, Cherai M, Le Gouvello S et al. Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood107(1), 381–388 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell JD, Cook G, Robertson SE et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF β is reversed by IL-15. J. Immunol.167(1), 553–561 (2001).
   Google Scholar
• Mariani S, Coscia M, Even J et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br. J. Haematol.113(4), 1051–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Vij R, Borrello I, Martin T et al. A Phase I/II study of Xcellerated T cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Blood102 (2003) (Abstract 139).
   Google Scholar
• Sze DM, Brown RD, Yang S et al. Clonally expanded T cells in myeloma with a late memory/effector phenotype are associated with improved survival. Blood102 (2003) (Abstract 3451).
   Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst.86(15), 1159–1166 (1994).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796), 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Jones E, Dahm-Vicker M, Simon AK et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol.2, 1 (2002).
   PubMedGoogle Scholar
• Vela-Ojeda J, Esparza MA, Reyes-Maldonado E et al. CD4+ CD25+ lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev.14(3), 310–316 (2005).
   Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med.194(6), 823–832 (2001).
   PubMed Web of Science ®Google Scholar
• Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med.187(1), 1–14 (1998).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med.191(4), 661–668 (2000).
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today11(7), 237–244 (1990).
   PubMedGoogle Scholar
• Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J. Immunol.172(3), 1333–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol.4(2), 175–181 (2003).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Tsang ML, Moretta L et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med.195(3), 343–351 (2002).
   PubMed Web of Science ®Google Scholar
• Zheng C, Ostad M, Andersson M et al. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. Br. J. Haematol.118(3), 778–785 (2002).
   Google Scholar
• Moretta L, Ferlazzo G, Mingari MC, Melioli G, Moretta A. Human natural killer cell function and their interactions with dendritic cells. Vaccine21(2), S38–S42 (2003).
   Google Scholar
• Frohn C, Hoppner M, Schlenke P et al. Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol.119(3), 660–664 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez M, San Miguel JF, Gascon A et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am. J. Hematol.39(2), 84–89 (1992).
   PubMed Web of Science ®Google Scholar
• El-Sherbiny YM, Davies FE, Cook G et al. NK cell repertoire in myeloma and the impact of thalidomide. Blood102(11) (2003) (Abstract 1617).
   Google Scholar
• Carbone E, Neri P, Mesuraca M et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood105(1), 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Geller MD, Chang DH et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med.197(12), 1667–1676 (2003).
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk. Lymphoma44(6), 997–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, von Lilienfeld-Toal M et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica86(10), 1029–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Pellicci DG et al. Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood99(4), 1259–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood108(2), 618–621 (2006).
   PubMed Web of Science ®Google Scholar
• Kitamura H, Iwakabe K, Yahata T et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med.189(7), 1121–1128 (1999).
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol.171(10), 5140–5147 (2003).
   PubMed Web of Science ®Google Scholar
• Galimberti S, Benedetti E, Morabito F et al. Different γ/δ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leuk. Res.30(5), 529–535 (2006).
   Google Scholar
• von Lilienfeld-Toal M, Nattermann J, Feldmann G et al. Activated γδ T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin. Exp. Immunol.144(3), 528–533 (2006).
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood102(1), 200–206 (2003).
   PubMed Web of Science ®Google Scholar
• Chen S, Zani C, Khouri Y et al. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther.2, 116–123 (1995).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Ono K, Ohtomo T, Yoshida K et al. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol. Immunol.36(6), 387–395 (1999).
   Google Scholar
• Treon SP, Agus TB, Link B et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J. Immunother.24(3), 272–279 (2001).
   Web of Science ®Google Scholar
• Lim SH, Zhang Y, Wang Z et al. Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood103(5), 1971–1972 (2004).
   PubMed Web of Science ®Google Scholar
• Musto P, Carella AM Jr, Greco MM et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br. J. Haematol.123(4), 746–747 (2003).
   PubMed Web of Science ®Google Scholar
• Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood103(6), 2332–2336 (2004).
   PubMed Web of Science ®Google Scholar
• Jones RJ. Differentiation of cancer stem cells. Exp. Hematol.31(7 Suppl. 1), S136 (2003).
   Google Scholar
• Musto P, Carella AM Jr, Greco MM et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br. J. Haematol.123(4), 746–747 (2003).
   PubMed Web of Science ®Google Scholar
• Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res.41(11 Pt 1), 4420–4425 (1981).
   PubMed Web of Science ®Google Scholar
• Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med.155(6), 1823–1841 (1982).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med.313(23), 1485–1492 (1985).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med.316(15), 889–897 (1987).
   PubMed Web of Science ®Google Scholar
• Lotze MT, Chang AE, Seipp CA et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA256(22), 3117–3124 (1986).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC et al. A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother.25(3), 243–251 (2002).
   PubMed Web of Science ®Google Scholar
• Ravaud A, Negrier S, Cany L et al. Subcutaneous low-dose recombinant interleukin 2 and α-interferon in patients with metastatic renal cell carcinoma. Br. J. Cancer69(6), 1111–1114 (1994).
   PubMed Web of Science ®Google Scholar
• Kiss TL, Spaner D, Daly AS et al. Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. Br. J. Haematol.120(3), 523–525 (2003).
   Google Scholar
• Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol.117(2), 297–305 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl Acad. Sci. USA96(5), 2268–2273 (1999).
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res.10(7), 2253–2264 (2004)
   PubMed Web of Science ®Google Scholar
• Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol.110(2–3), 139–148 (2003).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet352(9134), 1087–1092 (1998).
   PubMed Web of Science ®Google Scholar
• van Rhee F, Savage D, Blackwell J et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant.21(10), 1055–1061 (1998).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood89(9), 3129–3135 (1997).
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Zhan F et al. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood105(10), 3939–3944 (2005).
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother.43(3), 142–151 (1996).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood99(5), 1517–1526 (2002).
   PubMed Web of Science ®Google Scholar
• Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res.61(22), 8105–8109 (2001).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M et al.Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood102(4), 1435–1442 (2003).
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood101(3), 977–982 (2003).
   PubMed Web of Science ®Google Scholar
• Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood105(5), 1862–1866 (2005).
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J. Clin. Immunol.25(3), 177–188 (2005).
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Sanchez-Schmitz G, Angeli V. Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin. Immunopathol.26(3), 273–287 (2005).
   Google Scholar
• Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med.202(7), 919–929 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst.86(15), 1159–1166 (1994).
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med.11(11), 1230–1237 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson M, Wall DM, Hicks RJ, Prince HM. In vivo tracking for cell therapies. Quarterly J. Nucl. Med. Mol. Imag.49(4), 339–348 (2005).
   PubMed Web of Science ®Google Scholar